GeneDx Holdings Corp. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 9, 2026, reporting condensed consolidated financial statements and management discussion for the third quarter.

Key Highlights

  • Total assets: GeneDx reported total assets of $526,484 thousand as of September 30, 2026, compared to $523,710 thousand as of December 31, 2025.
  • Accumulated deficit: The accumulated deficit stood at $1,466,878 thousand at September 30, 2026, up from $1,373,495 thousand at December 31, 2025.
  • Long-term debt: Long-term debt, net of current portion, increased to $146,229 thousand from $48,176 thousand at year-end 2025.
  • Shares outstanding: 29,954,477 shares of Class A common stock were issued and outstanding as of September 30, 2026; as of November 2, 2026, that count was 29,972,493 shares.
  • Cash and marketable securities: Cash and cash equivalents were $96,139 thousand and marketable securities were $73,979 thousand at September 30, 2026.
  • Goodwill decline: Goodwill decreased to $1,641 thousand at September 30, 2026, from $13,520 thousand at December 31, 2025.
  • Total stockholders' equity: Stockholders' equity fell to $244,689 thousand from $308,182 thousand at December 31, 2025.

GeneDx Balance Sheet and Capital Position at September 30, 2026

According to the filing, GeneDx Holdings Corp. (NASDAQ:WGS) reported total current assets of $296,895 thousand as of September 30, 2026, compared to $268,288 thousand at December 31, 2025. The increase was driven in part by growth in accounts receivable, which rose to $92,131 thousand from $74,370 thousand, and inventory, net, which increased to $21,703 thousand from $13,951 thousand. Cash and cash equivalents declined to $96,139 thousand from $104,997 thousand over the same period, while marketable securities rose to $73,979 thousand from $66,285 thousand.

On the liabilities side, the filing disclosed that total liabilities increased to $281,795 thousand from $215,528 thousand at year-end 2025, primarily reflecting a rise in long-term debt, net of current portion, to $146,229 thousand from $48,176 thousand. Total current liabilities fell to $71,403 thousand from $108,908 thousand, with accounts payable and accrued expenses declining to $32,426 thousand from $57,645 thousand. The company reported goodwill of $1,641 thousand at September 30, 2026, down from $13,520 thousand at December 31, 2025, and intangible assets, net, of $137,732 thousand, down from $168,481 thousand.

The company's accumulated deficit grew by approximately $93,383 thousand during the nine months ended September 30, 2026, reaching $1,466,878 thousand. Additional paid-in capital increased to $1,711,675 thousand from $1,680,738 thousand. The filing noted that the registrant is classified as a large accelerated filer and is not a smaller reporting company or emerging growth company. The forward-looking statements in the filing are subject to the company's cautionary language and the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as the filing disclosed.

What Was Disclosed

GeneDx Holdings Corp. filed its quarterly report covering the period ended September 30, 2026, disclosing condensed consolidated balance sheet data, changes in stockholders' equity, and share counts, along with forward-looking statement cautionary language.